International Myeloma Society Practical Insights in and Translational Aspects of Novel Immune Therapies in Multiple Myeloma 2025

• Include:  videos + file sub vtt +  pdf, size:  GB
• Target Audience: Hematologists, Medical Oncologists, Pathologists, Infectious Disease Specialists, Ophthalmologists, Neurologists, and Immunologists
• Sample video: contact me for sample video
• Information:

Learning Objectives

At the conclusion of this educational activity, you will be able to:

Understand the types of patients who should be considered for novel immune based strategies including bispecific T cell engagers and CAR T cell therapy.

Understand the differences between TCEs, antibody drug conjugates, and CAR T cell process and data for appropriate care of the patient prior to consideration for these therapies.

Understand toxicities and their management post-novel immune strategies.

Target Audience

Are you a hematologist or oncologist treating patients with multiple myeloma?

If so, this workshop is for you!

This high-impact educational program, held in conjunction with the DGHO Annual Meeting, seeks to bridge the knowledge gap between CAR T administering centers and smaller community centers where the vast majority of oncology patients are treated, and raise awareness of novel immune based strategies including antibody drug conjugates, bispecific T cell engages, and CAR T therapies among healthcare professionals. The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.

Best for Hematologists, Medical Oncologists, Pathologists, Infectious Disease Specialists, Ophthalmologists, Neurologists, and Immunologists.

Topics

Advances in Diagnostics

Breakout Lesions/EMD

Single Cell Spatial Organization of Tumor Microenvironment

Advances in MRD Detection: Peripheral Blood and Bone Marrow Strategies

Monitoring for Infectious Post-T-Cell-Based Therapy

Predictors of Response and Mechanisms of Relapse

Treatment with Novel Agents/Novel Combinations/Novel Concepts

CelMOD (Combinations)

1 Line Therapy with Belamaf + Future Options

2 Line Therapy with Belamaf/Occular Management

Bispecific Combinations/Trispecifics

CART Cells in Earlier Lines

Management of Complications

CIDP Post-Cilta-cel

Immune Effector Cell Associated Secondary Malignancies

Bridging Therapies

Relapse Management

Modulation of the Target Antigen